Ironwood Pharmaceuticals Stock Fair Value Calculation – Ironwood Pharmaceuticals Reports Strong Earnings and Revenue Growth in Q4
May 6, 2023
Trending News ☀️
The company’s Non-GAAP EPS of $0.25 exceeded expectations by $0.01 while their revenue of $104.06M exceeded estimates by $3.46M. This comes as a positive sign for Ironwood Pharmaceuticals ($NASDAQ:IRWD), which is a publicly traded biotechnology company based in Cambridge, Massachusetts. The company develops and commercializes various gastrointestinal and cardiovascular medicines, such as Linaclotide, Gefapixant, and Lesinurad.
Their pipeline of new drugs includes a novel therapeutic for the treatment of irritable bowel syndrome with constipation, a new therapy for chronic kidney disease, and a first-in-class drug for the treatment of primary hyperoxaluria. Ironwood Pharmaceuticals is focused on bringing innovative treatments to patients worldwide, as well as continuing to deliver strong financial results to shareholders.
Earnings
IRONWOOD PHARMACEUTICALS recently released its earning report of FY2022 Q4 as of December 31 2022. Though total revenue decreased 8.5% year on year, net income increased 18.1%. In total, the company earned 107.2M USD in revenue and 48.87M USD in net income. This strong earning report demonstrates IRONWOOD PHARMACEUTICALS’s success and potential for future growth.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ironwood Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 410.6 | 175.06 | 42.6% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ironwood Pharmaceuticals. More…
| Operations | Investing | Financing |
| 273.76 | -0.14 | -237.55 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ironwood Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.1k | 448.14 | 3.86 |
Key Ratios Snapshot
Some of the financial key ratios for Ironwood Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -1.4% | 28.8% | 63.3% |
| FCF Margin | ROE | ROA |
| 66.6% | 26.1% | 14.8% |
Price History
The company’s stock opened at $10.5 and closed at $10.6, up 0.7% from its prior closing price of 10.5. This is a sign that investors are optimistic that its performance will continue to be strong. This number is largely driven by sales of its two main products, linaclotide and lesinurad. The 0.7% increase in the company’s stock price is a sign that investors are looking forward to further growth in the years to come. Live Quote…
Analysis – Ironwood Pharmaceuticals Stock Fair Value Calculation
At GoodWhale, we recently conducted an analysis of IRONWOOD PHARMACEUTICALS‘ wellbeing. Our proprietary Valuation Line revealed that the fair value of IRONWOOD PHARMACEUTICALS shares is around $27.8. However, as of present, its stock is traded at $10.6, leaving it undervalued by 61.9%. This presents a great opportunity for investors to get in on a great bargain. More…
Peers
Its competitors are Sun Pharma Advanced Research Co Ltd, Strides Pharma Science Ltd, Glenmark Pharmaceuticals Ltd.
– Sun Pharma Advanced Research Co Ltd ($BSE:532872)
Sun Pharma Advanced Research Co Ltd has a market cap of 70.81B as of 2022. The company’s Return on Equity is -429.91%. Sun Pharma Advanced Research Co Ltd is a pharmaceutical company that specializes in the research and development of new drugs and therapies. The company’s products are sold in over 100 countries worldwide.
– Strides Pharma Science Ltd ($BSE:532531)
Strides Pharma Science Ltd is a pharmaceutical company with a market cap of 29.66B as of 2022. The company has a Return on Equity of -10.94%. The company’s main products are generic drugs and active pharmaceutical ingredients. The company operates in over 50 countries and has over 10,000 employees.
– Glenmark Pharmaceuticals Ltd ($BSE:532296)
Glenmark Pharmaceuticals is a pharmaceutical company headquartered in Mumbai, India. The company was founded in 1977 by Gracias Saldanha as a generic drug manufacturer. The company has over 8,000 employees and operates in over 40 countries. The company’s product portfolio includes drugs in the areas of cardiology, dermatology, diabetes, oncology, respiratory, and urology.
Summary
Ironwood Pharmaceuticals recently reported strong fourth quarter results that beat analyst expectations. The results demonstrate Ironwood Pharmaceuticals’ continued success in delivering promising financial performance. Investors may want to consider adding Ironwood Pharmaceuticals to their portfolio as they have demonstrated strong growth potential and a competitive advantage in their market.
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
